Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ovo-like transcriptional repressor 1 (OVOL1) is a conserved zinc finger transcription factor that modulates epithelial and germ cell differentiation by repressing genes that maintain progenitor states. It is essential for transitions from proliferation to terminal differentiation in epithelial tissues, including hair follicles, kidney, and placenta. OVOL1 acts through dual mechanisms: it competes with transcriptional activators for promoter binding and actively recruits histone deacetylases via its SNAG domain, resulting in chromatin condensation and gene silencing[1][3][4]. In cancer, OVOL1 suppresses epithelial–mesenchymal transition, inhibits cell migration, and stabilizes SMAD7, making it a prognostic marker and potential therapeutic target in epithelial-derived tumors such as breast cancer[5].
Transcriptional repression by DNA binding to gene promoters; Competes with transcriptional activators such as c-Myb for DNA binding; Recruits histone deacetylases (HDAC1, HDAC2, HDAC3) via SNAG domain for chromatin remodeling and gene silencing; Stabilizes SMAD7 to suppress TGF-β receptor signaling, thereby inhibiting epithelial–mesenchymal transition in cancer
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ovo-like transcriptional repressor 1 (OVOL1).